Company Overview - Indaptus Therapeutics, Inc. is focused on immunotherapy, leveraging over a century of advancements in the field [3] - The company's approach involves activating both innate and adaptive immune cells through a multi-targeted package of immune system-activating signals that can be administered safely via intravenous (i.v.) methods [3] - Indaptus' patented technology utilizes non-pathogenic Gram-negative bacteria to produce a Decoy platform that acts as agonists for multiple immune receptors [3] Product Development - The Decoy product candidates have shown single-agent activity against various cancers, including metastatic pancreatic and colorectal carcinomas, and have demonstrated combination-mediated eradication of hepatocellular carcinomas and non-Hodgkin's lymphomas in pre-clinical models [5] - Pre-clinical studies indicate that these candidates can induce immunological memory and activate immune pathways with just one i.v. dose, transitioning tumors from a "cold" to a "hot" inflammation signature [5] - The Decoy candidates have also shown efficacy against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in pre-clinical models [5] Upcoming Events - CEO Jeffrey Meckler will present at Tribe Public's Webinar titled "Keys To The Kingdom: Unlocking The Power Of Your Immune System" on March 17, 2025 [1] - Participants can submit questions for the CEO during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [2]

Core Insights - Indaptus Therapeutics has secured new patent approvals in China, Japan, and Israel for its Decoy platform, which targets Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) [1][2][5] - The Decoy platform utilizes attenuated and killed bacteria to stimulate the immune system, showing significant activity against chronic HBV and HIV in preclinical studies [4][8] - The company is advancing its Decoy20 candidate in a Phase 1 clinical trial in the U.S. for patients with advanced cancers, further establishing its position in immunotherapy innovation [5][6] Industry Context - Chronic HBV infections are a major health concern, particularly in Asia, with approximately 87 million people affected in China and 1.1 to 1.2 million in Japan [7] - In 2022, HBV was responsible for an estimated 1.1 million deaths globally, primarily due to complications like cirrhosis and liver cancer [7] - The need for new therapies is urgent, as existing treatments do not sufficiently improve long-term outcomes for chronic infections [3][6]

Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections [1][4] - The company will present at the 10th Annual Innate Killer Summit, highlighting its Decoy platform designed to activate multiple arms of the immune system, including NK cells, to combat cancer [2][4] Company Overview - Indaptus Therapeutics has developed a novel approach based on the hypothesis that efficient activation of both innate and adaptive immune cells is necessary for effective anti-tumor and anti-viral responses [4] - The Decoy platform utilizes attenuated and killed non-pathogenic Gram-negative bacteria to produce a multi-targeted immune response, aiming to reduce intravenous toxicity while maintaining immune activation capabilities [4] Scientific Presentation - Dr. Michael Newman will present on March 4, 2025, discussing the use of attenuated and killed Gram-negative bacteria to induce NK-mediated anti-tumor immunity [2] - The presentation will emphasize the alignment of Indaptus' approach with next-generation immune-based therapies [2] Pre-Clinical Findings - Decoy product candidates have shown single-agent activity against various cancers, including metastatic pancreatic and colorectal carcinomas, and have demonstrated combination-mediated eradication in pre-clinical models [4] - The product candidates have also exhibited significant activity against chronic hepatitis B virus and chronic human immunodeficiency virus infections in pre-clinical studies [4]

Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections [1][4] - The company will present at the 10th Annual Innate Killer Summit, highlighting its Decoy platform designed to activate multiple arms of the immune system [2][4] Company Overview - Indaptus Therapeutics has a unique approach based on the hypothesis that effective activation of both innate and adaptive immune cells requires a multi-targeted package of immune system-activating signals [4] - The Decoy platform utilizes attenuated and killed non-pathogenic Gram-negative bacteria to produce a range of immune responses, including activation of Toll-like receptors (TLR), Nucleotide oligomerization domain (NOD)-like receptors (NLR), and Stimulator of interferon genes (STING) agonists [4] - The product candidates have shown promising results in pre-clinical studies, demonstrating activity against various cancers and chronic viral infections [4] Presentation Details - Dr. Michael Newman will present on March 4, 2025, discussing the use of attenuated and killed Gram-negative bacteria to induce NK-mediated anti-tumor immunity [2] - The presentation aims to align with the next generation of immune-based therapies and will be part of a conference focused on advancing NK cell strategies in oncology [2] Research and Development - The Decoy product candidates have demonstrated single-agent activity against metastatic pancreatic and colorectal carcinomas, as well as combination-mediated eradication of hepatocellular carcinomas and non-Hodgkin's lymphomas in pre-clinical models [4] - Pre-clinical studies have shown that the Decoy platform can induce immunological memory and activate both innate and adaptive immune pathways after a single intravenous dose [4] - The company has also observed meaningful activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in pre-clinical models [4]

Core Insights - Indaptus Therapeutics has received Clinical Trial Authorization from Health Canada to expand its clinical trial for Decoy20 into Canada, enhancing patient recruitment and clinical research [1][2] - The trial will involve weekly dosing of Decoy20 and aims to evaluate its effectiveness as a broad immune system activator in patients with solid tumors [1][2] - The company plans to submit an amendment to include a combination trial of Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab [1] Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, leveraging a patented technology that activates both innate and adaptive immune responses [3] - The Decoy platform consists of non-pathogenic Gram-negative bacteria designed to activate immune cells safely through intravenous administration [3] - Pre-clinical studies have shown Decoy product candidates' effectiveness against various cancers and chronic viral infections, demonstrating potential for significant therapeutic advances [3]

Core Points - Indaptus Therapeutics, Inc. has entered into securities purchase agreements for a private placement of 2,109,383 shares of common stock and accompanying warrants [1][3] - The effective purchase price for each share and associated warrants is $1.065, with gross proceeds expected to be approximately $2.25 million [1][3] - The warrants will have an exercise price of $0.94 per share, are immediately exercisable, and have a term of five years [2] Financial Details - The net proceeds from the offering will be used to fund research and development activities, working capital, and general corporate purposes [3] - The offering is expected to close on or about January 15, 2025, subject to customary closing conditions [1] Regulatory Information - The shares and warrants are offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b) of Regulation D [4] - The securities have not been registered under the Securities Act and may not be reoffered or resold in the U.S. without an effective registration statement or applicable exemption [4]

Core Insights - Indaptus Therapeutics has made significant progress in 2024, particularly with its lead clinical candidate, Decoy20, which is an innovative immunotherapy targeting cancer and viral infections [1][2] - The company has established a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab, highlighting the potential of Decoy20 as both a standalone therapy and in synergy with existing treatments [3] - Indaptus raised $5.5 million in 2024 to support ongoing research and development efforts, ensuring financial stability for future initiatives [5] Clinical Developments - Decoy20 demonstrated a broad immune response across multiple tumor types in patients during its Phase 1 clinical trial, indicating its potential as a monotherapy [4] - The company initiated a higher-dose weekly regimen for Decoy20 after positive safety reviews, expanding the trial's scope to assess safety and efficacy [4] - Key presentations at major industry conferences, including AACR and ASCO, showcased promising preliminary results and immune activation in patients treated with Decoy20 [4] Future Outlook - Indaptus plans to advance Decoy20 through clinical trials in 2025, focusing on its combination potential with BeiGene's tislelizumab [6] - The company aims to open a combination cohort in its clinical trial and expand the number of participating clinical sites to enhance patient enrollment [9] - Upcoming milestones in the first half of 2025 are expected to represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform [7] Scientific Foundation - The Decoy platform is based on a multi-targeted approach to activate both innate and adaptive immune responses, utilizing engineered Decoy bacteria to enhance therapeutic applications [8] - Pre-clinical studies have shown Decoy product candidates' effectiveness against various cancers and chronic viral infections, indicating a strong scientific foundation for future developments [10]

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share INDP Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Comm ...

Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (November 12, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, comm ...